Mismatch repair status and clinical outcome in endometrial cancer: A systematic review and meta-analysis

Critical Reviews in Oncology/Hematology

Volumn 88, Issue 1, 2013, Pages 154-167

  Diaz Padilla, Ivan ^a,b   Romero, Nuria ^a,c   Amir, Eitan ^b   Matias Guiu, Xavier ^d   Vilar, Eduardo ^e   Muggia, Franco ^f   Garcia Donas, Jesus ^a,c  

^a CEU Universities   (Spain)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endometrial cancer; Microsatellite instability; Mismatch repair; Prognosis

Indexed keywords

MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH6;

CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MISMATCH REPAIR; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; REVIEW; SYSTEMATIC REVIEW;

ENDOMETRIAL CANCER; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PROGNOSIS;

DNA MISMATCH REPAIR; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MICROSATELLITE INSTABILITY; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84884161920     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2013.03.002     Document Type: Review

References (49)

1. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Research 1998, 58:5248-5257.
2. Vilar E., Gruber S.B. Microsatellite instability in colorectal cancer-the stable evidence. Nature Reviews Clinical Oncology 2010, 7:153-162.
3. Hecht J.L., Mutter G.L. Molecular and pathologic aspects of endometrial carcinogenesis. Journal of Clinical Oncology 2006, 24:4783-4791.
4. Hendriks Y.M., de Jong A.E., Morreau H., et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA: A Cancer Journal for Clinicians 2006, 56:213-225.
5. Esteller M., Levine R., Baylin S.B., Ellenson L.H., Herman J.G. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998, 17:2413-2417.
6. Simpkins S.B., Bocker T., Swisher E.M., et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Human Molecular Genetics 1999, 8:661-666.
7. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960, 20:37-46.
8. Webb G.A., Brodsky L., O'Connell D., et al. An evaluation of the Newcastle Ottawa Scale: an assessment tool for evaluating the quality of non-randomized studies. XI International Cochrane Colloquium Book of Abstracts, vol. O-63 2003, 26.
9. DerSimonian R., Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986, 7:177-188.
10. Deeks J.J. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. British Medical Journal 2001, 323:157-162.
11. Umar A., Boland C.R., Terdiman J.P., et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute 2004, 96:261-268.
12. Bilbao C., Lara P.C., Ramirez R., et al. Microsatellite instability predicts clinical outcome in radiation-treated endometrioid endometrial cancer. International Journal of Radiation Oncology, Biology, Physics 2010, 76:9-13.
13. Bilbao C., Rodriguez G., Ramirez R., et al. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. International Journal of Cancer 2006, 119:563-570.
14. Black D., Soslow R.A., Levine D.A., et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. Journal of Clinical Oncology 2006, 24:1745-1753.
15. Fiumicino S., Ercoli A., Ferrandina G., et al. Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma. Journal of Clinical Oncology 2001, 19:1008-1014.
16. Mackay H.J., Gallinger S., Tsao M.S., et al. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). European Journal of Cancer 2010, 46:1365-1373.
17. Maxwell G.L., Risinger J.I., Alvarez A.A., Barrett J.C., Berchuck A. Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstetrics and Gynecology 2001, 97:417-422.
18. Caduff R.F., Johnston C.M., Svoboda-Newman S.M., Poy E.L., Merajver S.D., Frank T.S. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. American Journal of Pathology 1996, 148:1671-1678.
19. Zighelboim I., Goodfellow P.J., Gao F., et al. Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. Journal of Clinical Oncology 2007, 25:2042-2048.
20. Goodfellow P.J., Buttin B.M., Herzog T.J., et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:5908-5913.
21. Pijnenborg J.M., Dam-de Veen G.C., de Haan J., van Engeland M., Groothuis P.G. Defective mismatch repair and the development of recurrent endometrial carcinoma. Gynecologic Oncology 2004, 94:550-559.
22. Wong Y.F., Cheung T.H., Lo K.W., et al. Detection of microsatellite instability in endometrial cancer: advantages of a panel of five mononucleotide repeats over the National Cancer Institute panel of markers. Carcinogenesis 2006, 27:951-955.
23. Steinbakk A., Malpica A., Slewa A., et al. High frequency microsatellite instability has a prognostic value in endometrial endometrioid adenocarcinoma, but only in FIGO stage 1 cases. Analytical Cellular Pathology (Amsterdam) 2010, 33:245-255.
24. Blake P., Swart A.M., Orton J., et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009, 373:137-146.
25. Ma B.B., Oza A., Eisenhauer E., et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the National Cancer Institute of Canada Clinical Trials Group. International Journal of Gynecological Cancer 2004, 14:650-658.
26. Oza A.M., Eisenhauer E.A., Elit L., et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. Journal of Clinical Oncology 2008, 26:4319-4325.
27. Oza A.M., Elit L., Tsao M.S., et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. Journal of Clinical Oncology 2011, 29:3278-3285.
28. Resnick K.E., Frankel W.L., Morrison C.D., et al. Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. Gynecologic Oncology 2010, 117:234-238.
29. Cohn D.E., Frankel W.L., Resnick K.E., et al. Improved survival with an intact DNA mismatch repair system in endometrial cancer. Obstetrics and Gynecology 2006, 108:1208-1215.
30. Bakiewicz A., Michalak J., Sporny S. Immunoexpression and clinical significance of the PTEN and MLH1 proteins in endometrial carcinomas. Polish Journal of Pathology 2010, 61:185-191.
31. Peiro G., Diebold J., Mayr D., et al. Prognostic relevance of hMLH1, hMSH2, and BAX protein expression in endometrial carcinoma. Modern Pathology 2001, 14:777-783.
32. Stefansson I., Akslen L.A., MacDonald N., et al. Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clinical Cancer Research 2002, 8:138-143.
33. Arabi H., Guan H., Kumar S., et al. Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. Gynecologic Oncology 2009, 113:153-158.
34. Parc Y.R., Halling K.C., Burgart L.J., et al. Microsatellite instability and hMLH1/hMSH2 expression in young endometrial carcinoma patients: associations with family history and histopathology. International Journal of Cancer 2000, 86:60-66.
35. Kondo E., Furukawa T., Yoshinaga K., et al. Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. International Journal of Oncology 2000, 17:535-541.
36. Baldinu P., Cossu A., Manca A., et al. Microsatellite instability and mutation analysis of candidate genes in unselected sardinian patients with endometrial carcinoma. Cancer 2002, 94:3157-3168.
37. Wijnen J., de Leeuw W., Vasen H., et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nature Genetics 1999, 23:142-144.
38. Boland C.R., Koi M., Chang D.K., Carethers J.M. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Familial Cancer 2008, 7:41-52.
39. Senter L., Clendenning M., Sotamaa K., et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008, 135:419-428.
40. Gryfe R., Kim H., Hsieh E.T., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. New England Journal of Medicine 2000, 342:69-77.
41. Sinicrope F.A., Foster N.R., Thibodeau S.N., et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. Journal of the National Cancer Institute 2011, 103:863-875.
42. Zighelboim I., Powell M.A. Adjuvant treatment for early-stage endometrial cancer. Clinical Obstetrics and Gynecology 2011, 54:245-255.
43. Gadducci A., Greco C. The evolving role of adjuvant therapy in endometrial cancer. Critical Reviews in Oncology/Hematology 2011, 78:79-91.
44. Suraweera N., Duval A., Reperant M., et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002, 123:1804-1811.
45. Buhard O., Cattaneo F., Wong Y.F., et al. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. Journal of Clinical Oncology 2006, 24:241-251.
46. Pinol V., Castells A., Andreu M., et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. Journal of the American Medical Association 2005, 293:1986-1994.
47. Lindor N.M., Burgart L.J., Leontovich O., et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. Journal of Clinical Oncology 2002, 20:1043-1048.
48. Lanza G., Gafa R., Santini A., Maestri I., Guerzoni L., Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. Journal of Clinical Oncology 2006, 24:2359-2367.
49. Sargent D.J., Marsoni S., Monges G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. Journal of Clinical Oncology 2010, 28:3219-3226.